These results may provide novel strategies of glioma treatment, but the specific molecular mechanisms between MEG3 and Sirt7 require further investigation, and the functional role of MEG3 needs to be verified in in vivo experiments for future clinical application. This evidence concerns the gene SIRT7 and central nervous system cancer.